As SGYP and PGNX both await potential FDA approvals this year, BTIG’s Tim Chiang shares his positive two cents on these drug makers he believes present meaningful upside potential.
Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc.
In a research report published today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Progenics Pharmaceuticals (NASDAQ:PGNX) with a $11 price target, …
In a research report sent to investors today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Progenics (NASDAQ:PGNX) with an $11 price target, …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Progenics (NASDAQ:PGNX) with a $11 price target, …
